AI Article Synopsis
- An 80-year-old woman with a history of breast cancer presented with bloody sputum and multiple lung nodules, diagnosed as metastases through a biopsy.
- Initial treatment with denosumab and an aromatase inhibitor led to a 3-year period of tumor shrinkage, followed by regrowth of peritoneal metastases.
- After experiencing severe side effects from second-line chemotherapy, fulvestrant was administered, resulting in long-term tumor shrinkage without negatively impacting her quality of life; this case highlights a rare recurrence of breast cancer 32 years post-surgery.
Article Abstract
An 80-year-old woman presented with blood-stained sputum. Computed tomography revealed the presence of multiple lung nodules. The patient underwent surgery for left breast cancer at 48 years of age. A transbronchial lung biopsy was performed to identify the primary tumor. The pathological diagnosis was adenocarcinoma and immunohistochemical staining indicated that the lung nodules were breast cancer metastases. Positron emission tomography revealed multiple metastases to the bones, skin, peritoneum, and mesenteric lymph nodes. The patient indicated that the quality of life was a critical factor in selecting therapy. Denosumab and an aromatase inhibitor were selected as the first-line systemic chemotherapies. The treatment resulted in tumor shrinkage that lasted for 3 years, after which the peritoneal metastases started to regrow. We recommended tegafur/gimeracil/oteracil as second-line chemotherapy, which the patient discontinued within 1 month because of severe side effects. We next administered fulvestrant, which resulted in the long-term shrinkage of most tumors without regrowth. This treatment did not negatively affect patients' quality of life. Some breast cancers recur ≥5 years after the primary surgery. Therefore, this is a very rare case of breast cancer recurrence with an interval of 32 years after the initial treatment.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Trastuzumab deruxtecan in human epidermal growth factor receptor 2-positive breast cancer brain metastases: A systematic review and updated meta-analysis.
Cancer Treat Rev
January 2025
Division of Hematology and Oncology, University of Virginia Comprehensive Cancer Center, Charlottesville, VA, United States. Electronic address:
Background: Trastuzumab deruxtecan (T-DXd) has shown promising activity in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) and central nervous system (CNS) involvement. In this updated meta-analysis, we explore the effectiveness of T-DXd in a large subset of patients with HER2-positive BC and CNS disease.
Methods: A systematic search was made on September 16th, 2024, for studies investigating T-DXd in the scenario of HER2-positive BC and brain metastases (BMs) and/or leptomeningeal disease (LMD).
Synthesis of complex, multiring, spirocyclic, 1,3-dicarbonyl fused, and highly functionalized 5-phenyl-1-azabicyclo[3.1.0]hexanes (ABCH) has been achieved by an intermolecular reaction of 2-(2'-ketoalkyl)-1,3-indandiones or α,γ-diketo esters with (1-azidovinyl)benzenes under transition metal-free conditions.
View Article and Find Full Text PDFSupervised Exercise for Patients With Metastatic Breast Cancer: A Cost-Utility Analysis Alongside the PREFERABLE-EFFECT Randomized Controlled Trial.
J Clin Oncol
January 2025
Department of Epidemiology and Health Economics, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
Purpose: To evaluate the cost utility of a 9-month supervised exercise program for patients with metastatic breast cancer (mBC), compared with control (usual care, supplemented with general activity advice and an activity tracker). Evidence on the cost-effectiveness of exercise for patients with mBC is essential for implementation in clinical practice and is currently lacking.
Methods: A cost-utility analysis was performed alongside the multinational PREFERABLE-EFFECT randomized controlled trial, conducted in 8 centers across Europe and Australia.
ODSEI Chip: An Open 3D Microfluidic Platform for Studying Tumor Spheroid-Endothelial Interactions.
Adv Sci (Weinh)
January 2025
Department of Biomedical Engineering, Ulsan National Institute of Science and Technology (UNIST), Ulsan, 44919, South Korea.
Current in vitro models of 3D tumor spheroids within the microenvironment have emerged as promising tools for understanding tumor progression and potential drug responses. However, creating spheroids with functional vasculature remains challenging in a controlled and high-throughput manner. Herein, a novel open 3D-microarray platform is presented for a spheroid-endothelium interaction (ODSEI) chip, capable of arraying more than 1000 spheroids on top of the vasculature, compartmentalized for single spheroid-level analysis of drug resistance, and allows for the extraction of specific spheroids for further analysis.
View Article and Find Full Text PDFThe current landscape of personalised preventive approaches for non-communicable diseases: A scoping review.
PLoS One
January 2025
University Department of Life Science and Public Health, Section of Hygiene, Università Cattolica del Sacro Cuore, Rome, Italy.
Introduction: Personalised prevention offers a promising tool to reduce the impact of non-communicable diseases, which represent a growing health burden worldwide. However, to support the adoption of this innovation it is needed to clarify the current state of available evidence in this area. This work aims to provide an overview of recent publications on personalised prevention for chronic conditions.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!